Beta-blocker therapy reduced the risk of death or major adverse cardiovascular events by 15% in patients with MI and a LVEF ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and Amgen’s Tepezza.

Developed by Johnson & Johnson, guselkumab is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.4,12,13 ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studiesIcotrokinra also showed ...

Around the world, governments, industries, and technology providers are preparing for the migration to post-quantum cryptography (PQC). Standards bodies such as NIST in the United States and ENISA in ...

This polymer-based system shows that coherent quantum behavior can be designed into stable, tunable, solution-processable ...

A new study published in Nature Medicine provides more evidence that ketamine’s rapid antidepressant effects may be partially ...

Vir Biotechnology, Inc. ( NASDAQ: VIR) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT ...

Share function enhances your interplay by permitting you to ship and obtain media recordsdata together with your chat partner ...

While you may have been distracted by Apple’s new product releases and interesting operating system enhancements, the company ...

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of ...